Gonorrhea Clinical Trials

Find Gonorrhea Clinical Trials Near You

A First in Human Phase I Randomized and Controlled Trial to Test Safety and Immunogenicity of a Multivalent Vaccine Against Neisseria Gonorrhoeae

Status: Recruiting
Location: See location...
Intervention Type: Biological, Other
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The main goal of this trial is to evaluate the safety and immunogenicity of the candidate N. gonorrhoeae vaccine, LTB-NG6.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 50
Healthy Volunteers: t
View:

• Aged 18-50 years (inclusive) at the time of the first injection

• Good and stable general health, determined by medical history, laboratory findings and physical examination as judged by the Investigator before receiving the first injection.

• Willingness and ability to comply with the requirements of the protocol (e.g., completion of the diary forms, return for follow-up visits)

• Signed written informed consent obtained

• Availability for the trial duration, including all planned follow-up visits and phone calls

• Negative urine pregnancy test for WOCBP. WOCBP must be willing to use a highly effective method of contraception during the trial

Locations
Other Locations
Germany
Nuvisan GmbH
RECRUITING
Neu-ulm
Contact Information
Primary
Steffen Haffner, Dr.
Steffen.Haffner@nuvisan.com
+49 731 9840 452
Backup
Christian Reh, Dr.
Christian.Reh@nuvisan.com
+49 731 9840 131
Time Frame
Start Date: 2026-08-19
Estimated Completion Date: 2027-09-23
Participants
Target number of participants: 142
Treatments
Placebo_comparator: Placebo
Participants receive 2 administrations of Sodium chloride 0.9%
Experimental: Dose 1
Participants receive 2 Dose 1 administrations of the investigational product
Experimental: Dose 2
Participants receive 2 Dose 2 administrations of the investigational product
Experimental: Dose 3
Participants receive 2 Dose 3 administrations of the investigational product
Experimental: Dose 4
Participants receive 2 Dose 4 administrations of the investigational product
Experimental: Dose 5
Participants receive 2 Dose 5 administrations of the investigational product
Related Therapeutic Areas
Sponsors
Collaborators: Wellcome Trust, Novo Nordisk Foundation, Nuvisan, Germany, German Federal Ministry of Education and Research
Leads: LimmaTech Biologics AG

This content was sourced from clinicaltrials.gov